FDA approves first at-home shot for thyroid eye disease
Published
Roche's Enspryng, already used for a rare nerve disorder, can now be self-injected every four weeks by adults with thyroid eye disease. In one of two main trials, about 53% of patients had less eye bulging versus 23% on placebo; the other trial missed its main goal.
Source: Roche
This is a plain-language summary. Read the original source for full details.